Long-term joint health study with efanesoctocog alfa
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A (a bleeding disorder).
- You are prescribed efanesoctocog alfa (a factor VIII treatment) for prevention within the last 6 months or at your first visit.
- You have been on some hemophilia prevention treatment for at least 12 months before starting efanesoctocog alfa.
- You are willing to keep a diary of any bleeding episodes and treatments.
- You agree to have joint health checks, and if in the ultrasound group, yearly scans of your ankles, elbows, and knees.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This study compares how two different hemophilia A treatments affect bone strength and health in men over time. Researchers will track bone density and collect blood samples to understand whether one treatment protects bones better than the other.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.